Detailed view for Tb927.10.7780
Basic information
Trypanosoma brucei, Mitogen-activated protein kinase KFR1
Source Database / ID: TriTrypDB GeneDB
pI: 5.264 |
Length (AA): 350 |
MW (Da): 39358 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Network
Pfam domains
Gene Ontology
GO:0004713 protein tyrosine kinase activity
GO:0004707 MAP kinase activity
GO:0004674 protein serine/threonine kinase activity
GO:0004672 protein kinase activity
GO:0006468 protein amino acid phosphorylation
Metabolic Pathways
Structural information
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
| Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
|---|---|---|---|---|---|---|---|---|---|
| 5 | 350 | 4lgd (A) | 18 | 450 | 28.00 | 0 | 1 | 1.12427 | 0.52 |
| 7 | 349 | 3oz6 (A) | 4 | 380 | 40.00 | 0 | 1 | 1.413 | -0.69 |
| 9 | 340 | 2b9h (A) | 8 | 351 | 39.00 | 0 | 1 | 1.46327 | -0.83 |
| 13 | 344 | 5hd4 (A) | 22 | 353 | 36.00 | 0 | 1 | 1.46127 | -0.91 |
Help me make sense of these data.
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Expression
| Upregulation Percent | Ranking | Stage | Dataset |
|---|---|---|---|
| Upper 60-80% percentile | Procyclic, Bloodstream Form. | Siegel TN |
-
Siegel TN Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites.
Orthologs
Ortholog group members (OG5_151344)
| Species | Accession | Gene Product |
|---|---|---|
| Leishmania braziliensis | LbrM.35.6810 | mitogen activated protein kinase homologue,map-kinase homologue |
| Leishmania donovani | LdBPK_366760.1 | mitogen activated protein kinase homologue |
| Leishmania infantum | LinJ.36.6760 | mitogen activated protein kinase homologue,map-kinase homologue |
| Leishmania major | LmjF.36.6470 | mitogen activated protein kinase homologue,map-kinase homologue |
| Leishmania mexicana | LmxM.20_36.6470 | |
| Trypanosoma brucei gambiense | Tbg972.10.9540 | protein kinase, putative |
| Trypanosoma brucei | Tb927.10.7780 | Mitogen-activated protein kinase KFR1 |
| Trypanosoma congolense | TcIL3000_10_6640 | protein kinase, putative |
| Trypanosoma cruzi | TcCLB.504167.30 | mitogen-activated protein kinase 1, putative |
Essentiality
| Gene/Ortholog | Organism | Phenotype | Source Study |
|---|---|---|---|
| Tb927.10.7780 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
| Tb927.10.7780 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
| Tb927.10.7780 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
| Tb927.10.7780 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
-
nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource -
yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database -
shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan -
gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84 -
neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs -
blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930 -
alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924 -
wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170 -
keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
Phenotypes and Validation (curated)
Annotated phenotypes:
| Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
|---|---|---|---|---|---|---|
| cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
| cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in procyclic forms . | References: | 21363968 | |
| cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
| Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 | |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Annotated validation
Associated compounds / Druggability
Druggability index (range: 0 to 1): 0.7
Known modulators for this target
Predicted associations
By orthology with druggable targets
By sequence similarity to non orthologous druggable targets
| Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
|---|---|---|---|---|---|---|
| Schizosaccharomyces pombe 972h- | Casein kinase II subunit alpha | 332 aa | 25.2% | 298 aa | Compounds | References |
| Patiria pectinifera | Cdc2 | 300 aa | 35.5% | 299 aa | Compounds | References |
| Oryctolagus cuniculus | Cyclin-dependent kinase 4 | 189 aa | 40.0% | 170 aa | Compounds | References |
| Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 36.7% | 297 aa | Compounds | References |
| Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 36.4% | 297 aa | Compounds | References |
| Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 36.5% | 304 aa | Compounds | References |
Obtained from network model
Ranking Plot
Putative Drugs List
Assayability
Assay information
Reagent availability
Bibliographic References
1 literature reference was collected for this gene.